Duopharma Biotech Berhad Statistics

Total Valuation

KLSE:DPHARMA has a market cap or net worth of MYR 1.15 billion. The enterprise value is 1.41 billion.

Market Cap	1.15B
Enterprise Value	1.41B

Important Dates

The next estimated earnings date is Friday, May 16, 2025.

Earnings Date	May 16, 2025
Ex-Dividend Date	Mar 5, 2025

Share Statistics

KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has increased by 0.36% in one year.

Current Share Class	n/a
Shares Outstanding	961.94M
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.31%
Owned by Institutions (%)	71.94%
Float	454.59M

Valuation Ratios

The trailing PE ratio is 18.43 and the forward PE ratio is 13.11. KLSE:DPHARMA's PEG ratio is 0.69.

PE Ratio	18.43
Forward PE	13.11
PS Ratio	1.42
PB Ratio	1.63
P/TBV Ratio	1.74
P/FCF Ratio	19.29
P/OCF Ratio	n/a
PEG Ratio	0.69

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.62, with an EV/FCF ratio of 23.48.

EV / Earnings	22.43
EV / Sales	1.73
EV / EBITDA	9.62
EV / EBIT	13.96
EV / FCF	23.48

Financial Position

The company has a current ratio of 4.10, with a Debt / Equity ratio of 0.73.

Current Ratio	4.10
Quick Ratio	2.70
Debt / Equity	0.73
Debt / EBITDA	3.53
Debt / FCF	8.61
Interest Coverage	3.79

Financial Efficiency

Return on equity (ROE) is 8.97% and return on invested capital (ROIC) is 5.11%.

Return on Equity (ROE)	8.97%
Return on Assets (ROA)	4.62%
Return on Invested Capital (ROIC)	5.11%
Return on Capital Employed (ROCE)	8.39%
Revenue Per Employee	493,148
Profits Per Employee	37,967
Employee Count	1,650
Asset Turnover	0.60
Inventory Turnover	2.08

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	0.74
52-Week Price Change	n/a
50-Day Moving Average	1.23
200-Day Moving Average	1.25
Relative Strength Index (RSI)	45.53
Average Volume (20 Days)	156,260

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KLSE:DPHARMA had revenue of MYR 813.70 million and earned 62.65 million in profits. Earnings per share was 0.07.

Revenue	813.70M
Gross Profit	301.54M
Operating Income	100.65M
Pretax Income	80.02M
Net Income	62.65M
EBITDA	146.08M
EBIT	100.65M
Earnings Per Share (EPS)	0.07

Full Income Statement

Balance Sheet

The company has 264.55 million in cash and 515.35 million in debt, giving a net cash position of -250.81 million or -0.26 per share.

Cash & Cash Equivalents	264.55M
Total Debt	515.35M
Net Cash	-250.81M
Net Cash Per Share	-0.26
Equity (Book Value)	709.15M
Book Value Per Share	0.74
Working Capital	549.62M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 82.16 million and capital expenditures -22.33 million, giving a free cash flow of 59.84 million.

Operating Cash Flow	82.16M
Capital Expenditures	-22.33M
Free Cash Flow	59.84M
FCF Per Share	0.06

Full Cash Flow Statement

Margins

Gross margin is 37.06%, with operating and profit margins of 12.37% and 7.70%.

Gross Margin	37.06%
Operating Margin	12.37%
Pretax Margin	9.83%
Profit Margin	7.70%
EBITDA Margin	17.95%
EBIT Margin	12.37%
FCF Margin	7.35%

Dividends & Yields

This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.50%.

Dividend Per Share	0.03
Dividend Yield	2.50%
Dividend Growth (YoY)	30.43%
Years of Dividend Growth	1
Payout Ratio	42.99%
Buyback Yield	-0.36%
Shareholder Yield	2.14%
Earnings Yield	5.43%
FCF Yield	5.18%

Dividend Details

Stock Splits

The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.

Last Split Date	Sep 6, 2021
Split Type	Forward
Split Ratio	1.3333333333

Scores

KLSE:DPHARMA has an Altman Z-Score of 2.74. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.74
Piotroski F-Score	n/a